Anixa Biosciences (NASDAQ:ANIX) CEO Amit Kumar Purchases 5,000 Shares

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar purchased 5,000 shares of the business’s stock in a transaction on Friday, July 31st. The stock was acquired at an average price of $3.47 per share, with a total value of $17,350.00. Following the completion of the acquisition, the chief executive officer directly owned 657,000 shares in the company, valued at $2,279,790. The trade was a 0.77% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Amit Kumar also recently made the following trade(s):

• On Friday, July 24th, Amit Kumar bought 3,000 shares of Anixa Biosciences stock. The shares were acquired at an average price of $3.73 per share, for a total transaction of $11,190.00.
• On Monday, July 20th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The shares were bought at an average price of $3.46 per share, for a total transaction of $17,300.00.
• On Monday, July 27th, Amit Kumar purchased 3,188 shares of Anixa Biosciences stock. The shares were bought at an average cost of $3.37 per share, for a total transaction of $10,743.56.
• On Monday, July 27th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The stock was purchased at an average price of $3.44 per share, for a total transaction of $17,200.00.
• On Friday, July 10th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The stock was purchased at an average cost of $3.04 per share, for a total transaction of $15,200.00.
• On Friday, June 12th, Amit Kumar purchased 21,000 shares of Anixa Biosciences stock. The shares were acquired at an average cost of $2.50 per share, for a total transaction of $52,500.00.

Anixa Biosciences Trading Down 0.3%

Shares of Anixa Biosciences stock opened at $3.41 on Tuesday. Anixa Biosciences Inc has a twelve month low of $2.32 and a twelve month high of $5.46. The company has a fifty day moving average price of $2.98 and a 200 day moving average price of $2.93. The stock has a market cap of $116.01 million, a price-to-earnings ratio of -11.00 and a beta of 0.55.

Anixa Biosciences (NASDAQ:ANIX) last posted its earnings results on Wednesday, June 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. Analysts forecast that Anixa Biosciences Inc will post -0.31 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on ANIX. HC Wainwright reissued a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. D. Boral Capital restated a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. Finally, Zacks Research upgraded Anixa Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Anixa Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

Hedge Funds Weigh In On Anixa Biosciences

Several large investors have recently made changes to their positions in the business. 683 Capital Management LLC bought a new stake in shares of Anixa Biosciences during the 4th quarter worth $355,000. ExodusPoint Capital Management LP purchased a new stake in Anixa Biosciences in the 4th quarter worth about $293,000. Susquehanna International Group LLP boosted its position in Anixa Biosciences by 378.4% during the 3rd quarter. Susquehanna International Group LLP now owns 80,387 shares of the company’s stock worth $265,000 after acquiring an additional 63,584 shares during the period. Virtu Financial LLC acquired a new stake in Anixa Biosciences during the 4th quarter worth about $161,000. Finally, State Street Corp boosted its holdings in shares of Anixa Biosciences by 32.0% during the fourth quarter. State Street Corp now owns 159,040 shares of the company’s stock worth $496,000 after purchasing an additional 38,540 shares during the period. Institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.